Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NRXP
NRXP | US
2.52
USD0.02
0.80%
NRXP | US
About NRXP
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
15/04/2026
Close
2.52
Open
2.51
High
2.58
Low
2.41
NRX Pharmaceuticals Inc. a clinical-stage pharmaceutical company develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington Delaware.
View LessNRXP | US
Risk
106.9
Sharpe
0.23
Luna's Score
48/100
Recommendation
Hold
Luna says (NRXP | US)
What's Working
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
49.2%1 month
106.9%3 months
87.8%6 months
82.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.90
Debt to equity
-0.47
Debt to assets
1.63
Ent. to EBITDA
-0.15
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-23.26M
MarketCap
27.09M
MarketCap(USD)
27.09M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-682.61
Short ratio
5.82
Short perc.
5.99
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.47
Range1M
0.86
Range3M
0.96
Volumes: Market Activity
Rel. volume
1.19
Price X volume
2.73M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.15 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.90 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 87.82 | - | Riskier |
| Debt to Equity | -0.47 | -1.23 | Expensive |
| Debt to Assets | 1.63 | 0.25 | Expensive |
| Market Cap | 27.09M | - | Emerging |
